Teva Pharmaceutical Industries LimitedTEVA
NYSE•Healthcare•Drug Manufacturers - Specialty & Generic
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $17.35B, growing 4.4% year-over-year. TTM net income stood at $1.57B (218.7% growth). Quarterly EBITDA was $891.00M and operating income was $652.00M. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze TEVA growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters